326 results about "Immune escape" patented technology

The invention discloses a lung adenocarcinoma prognosis risk prediction model and a construction method and application thereof, and belongs to the technical field of biomedical detection. The lung adenocarcinoma (LUAD) prognosis model is successfully constructed by systematically analyzing the immune infiltration related gene (CAFRG) of tumor-associated fibroblasts (CAF), and the application value of the lung adenocarcinoma (LUAD) prognosis model in prediction of patient prognosis is verified. The CAFRG risk score is negatively related to the immune microenvironment score and is remarkably related to immune checkpoint gene expression, which suggests that a high-risk patient may have the characteristic of immune escape. Furthermore, based on TIDE tool analysis, the patients in the low-risk group have more active T cell immune response. The risk score is also closely related to the sensitivity of antitumor drugs, especially Doramapimod. Therefore, a new theoretical basis is provided for personalized treatment of lung adenocarcinoma, and a new direction is provided for future clinical research.

The invention discloses a bispecific nano antibody targeting CXCL1 and PD-L1 and application thereof, and belongs to the technical field of antibody engineering and bioengineering. The bispecific nano-antibody targeting CXCL1 and PD-L1 comprises at least one nano-antibody for recognizing a target CXCL1 and a nano-antibody for recognizing a target PD-L1, and nano-antibody monomers are connected through a linker. The bispecific nano-antibody targeting PD-L1 / CXCL1 provided by the invention has a unique structure, so that the bispecific nano-antibody targeting PD-L1 / CXCL1 has specific recognition and binding capacities to CXCL1 and PD-L1, the affinity to CXCL1 reaches 1.08 nM, the affinity to PD-L1 reaches 1.09 nM, drug resistance of a patient to antibody treatment caused by immune escape can be effectively prevented, and the bispecific nano-antibody targeting PD-L1 / CXCL1 is suitable for more patients and has good clinical application prospects. And a new thought is provided for CRC treatment.

The invention relates to application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention discloses application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer. The GATA3 regulates the transcription regulation of IFNbeta by inhibiting the enhancer activity of IFNB1, down-regulates an I-type interferon signal channel, inhibits the secretion of an MHC-I antigen presentation channel and a chemotactic factor CCL5 of breast cancer cells, reduces immune recognition, and achieves the purpose of immune escape. The immunotherapy for inhibiting GATA3 combined with the PD1 inhibitor to treat breast cancer effectively treats breast cancer mice, improves the IFN beta level in the mice, promotes the MHC-I antigen presentation pathway of the mice, improves the CCL5 level in the mice, and improves the CD8 + T cell level in a tumor immune microenvironment, thereby reducing tumor occurrence and inhibiting tumor growth.

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The invention provides a genetically engineered bacterial exosome vesicle and application thereof in preparation of a medicine for treating tumors, and comprises a genetically engineered bacterial exosome vesicle Neo-MICBOMVs, and the surface of the genetically engineered bacterial exosome vesicle Neo-MICBOMVs is loaded with a fusion protein composed of a tumor neoantigen protein and an MICB [alpha] 3 structural domain protein. The fusion protein can be used as a vaccine pharmaceutical composition for treating tumors, can be used as a targeting antigen presenting cell, can promote activation of an immune system, can increase immune infiltration in a tumor microenvironment, can inhibit immune escape of tumor cells, and can improve the effect of tumor immunotherapy.

The invention relates to the technical field of biological medicine, in particular to the field of cell therapy, and particularly relates to application of STAR and immune cells comprising the STAR to treatment and / or prevention of tumors, an antigen binding region of the STAR comprises one or more than two of an antibody, a ligand or an antibody fusion body which binds to LILRB4, the antibody such as scFv or VHH, and the ligand and the antibody fusion body can be combined with the LILRB4. Wherein the LILRB4 is used as a tumor antigen and / or a receptor in an immunosuppressive active cell. According to the invention, the targeted killing effect of immune cells on tumors is enhanced by targeting tumor cells and / or reducing immune escape caused by immunosuppressive active cells.

The invention discloses a dual-targeting bionic liposome composite material and a preparation method and application thereof, and belongs to the technical field of nano-medices.The dual-targeting bionic liposome composite material is prepared by taking liposome nano-particles as a carrier, loading iloumab and alkannin on the carrier to obtain drug-loaded liposome, and fusing the drug-loaded liposome with a macrophage membrane to obtain the dual-targeting bionic liposome composite material. And modifying with phospholipidic hyaluronic acid to obtain the double-targeting bionic liposome composite material. According to the invention, two anti-atherosclerosis effects with different mechanisms, i.e., lipid lowering by Elolukumab and anti-inflammation by alkannin, are utilized to realize targeted therapy of atherosclerosis, and the bionic membrane on the outermost layer realizes long blood circulation and lesion site targeting ability of the composite material through inherent immune escape and recruitment characteristics of macrophages. The characteristic that hyaluronic acid interacts with a target cell surface receptor CD44 is utilized, effective utilization of the target cell on the composite material is achieved, and the atherosclerosis prevention and treatment effect of the composite material is improved.

The invention discloses a new coronavirus variant prediction method and system with higher immune escape ability, a conditional generative adversarial network model and a variational self-encoding model are used for data expansion, the similarity between an expanded data set and a constructed original data set is compared, the expanded data set with the highest quality is incorporated into the original data set, and the new coronavirus variant prediction method and system with the higher immune escape ability are obtained. Obtaining an expanded data set; inputting the RBD amino acid sequence in the expanded data set and label data for determining whether the RBD amino acid sequence is combined with a human receptor ACE2 and eight antibodies or not into a constructed multi-task classification deep network model for training and verification to obtain an immune escape score of a virus variant corresponding to the RBD amino acid sequence; a new RBD sequence is generated by using the fitness in an immune escape score quantification genetic algorithm framework, a sequence generation strategy is optimized based on an adversarial generation method to obtain an RBD sequence with higher immune escape ability and an immune escape score thereof, and prediction of a new coronavirus variant is realized.

The invention relates to the technical field of medical care informatics, in particular to a respiratory infectious disease risk early warning method and system. The method comprises the following steps: acquiring a respiratory tract sample of a mutant virus infected person; the method comprises the following steps: extracting a mutant virus from a respiratory tract sample, carrying out genome sequencing on the mutant virus, positioning starting and ending positions of a spike protein coding gene in a genome by virtue of a biological information comparison method, extracting a spike protein coding sequence, and translating the spike protein coding sequence into an amino acid sequence; inputting the amino acid sequence into an immune escape prediction model to predict the immune escape score of the mutant virus; and performing risk assessment based on the immune escape score in combination with clinical monitoring information, and outputting a respiratory infectious disease risk early warning value. According to the invention, the risk of respiratory infectious diseases can be early warned better.

The invention discloses a colorectal cancer prognosis model construction method based on fatty acid metabolism related genes, and belongs to the technical field of biomedicine, and the colorectal cancer prognosis model construction method comprises the following steps: S1, obtaining transcriptome data of a colorectal cancer diagnosis individual from a TCGA database; s2, performing difference analysis on fatty acid metabolism related gene expression data of the colorectal cancer tissue and the normal tissue, and screening out differentially expressed genes; s3, performing single-factor Cox regression analysis on the differentially expressed genes, and screening out genes related to colorectal cancer prognosis; according to the construction method of the colorectal cancer prognosis model based on the fatty acid metabolism related genes, provided by the invention, the tumor immunotherapy reactivity is evaluated by introducing TIDE scores, and the prior art is improved, so that the immune escape potential and the immunotherapy effect of tumor subtypes are analyzed. The prognosis of a colorectal cancer patient is effectively predicted, and a new molecular marker is provided for personalized treatment of the colorectal cancer.

The invention relates to the technical field of photo-thermal therapy, in particular to a monomolecular photo-thermal agent with high photo-thermal conversion efficiency and a preparation method and application of the monomolecular photo-thermal agent. The preparation method comprises the following steps: S1, synthesis of a compound X1: under the protection of argon, dissolving 2, 4-dimethyl pyrrole in dichloromethane, stirring in an ice bath, adding trifluoroacetic anhydride, heating to room temperature after stirring, extracting after quenching reaction, combining organic phases, drying, filtering, concentrating under reduced pressure and purifying by silica gel column chromatography to obtain the compound X1. The prepared monomolecular photothermal agent with the high photothermal conversion efficiency is high in water solubility, has the high photothermal conversion efficiency in an aqueous solution and is high in light stability, the immune escape phenomenon possibly caused by introduction of a high polymer material is avoided, and the technical problem that an existing photothermal agent is difficult to achieve the high photothermal conversion efficiency in the aqueous solution is solved.

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention belongs to the technical field of tumor vaccines, and particularly relates to an mRNA (messenger Ribonucleic Acid) vaccine for coding tumor antigen epitopes as well as a preparation method and application thereof. In order to overcome the defect of immune escape caused by insufficiency or loss of a single antigen, the invention provides an mRNA vaccine capable of simultaneously coding a plurality of tumor antigen epitopes, and the tumor antigen epitopes are selected from high-frequency mutation epitopes of human tumor driving genes, such as G12D, G12V and G12C mutations of RAS genes; the antigenic epitopes can be used for preparing antigenic epitopes related to common viruses of human tumors, such as HPV16E6 / E7, EBV LAMP1 or CMV pp65, and tumor high-expression carcino-embryonic antigen gene epitopes, such as MAGE-A4, NY-ESO-1, WT1, and the like. The mRNA vaccine is obtained by serially expressing a plurality of tumor antigen epitopes and encapsulating and delivering lipid nanoparticles. Experiments prove that the compound can effectively prevent and treat various tumors and has a wide application prospect.

The invention relates to the technical field of tumor immunotherapy, in particular to a dual-targeting chimeric antigen receptor, a recombinant expression vector, an anti-tumor natural killer cell and application, and provides a PD1-DAP10-41BB-P2A-NKG2D-Ig4-CD28-41BB-CD3 zeta fusion receptor.The dual-targeting chimeric antigen receptor can target PD-L1 on the surface of a tumor cell, can also recognize NKG2DLs and can be used for preparing anti-tumor natural killer cells. The broad spectrum of the NK cells is greatly improved, and meanwhile, the immune escape of tumor cells is also reduced.

The invention relates to preparation of a pancreatic cancer dendritic cell vaccine and application of the pancreatic cancer dendritic cell vaccine in treatment of pancreatic cancer, relates to the technical field of biological medicines, and comprises a preparation method of Panc-1 and AsPC-1 lysates, a preparation method of a DC vaccine loaded with the Panc-1 and AsPC-1 lysates and function verification of DC cells. The DC vaccine prepared by the invention not only stimulates T cells to generate more IFN-gamma, but also induces to generate stronger tumor killing T cells, and provides a new thought for research and development of pancreatic cancer DC vaccines. In addition, Panc-1 and AsPC-1 lysates are adopted as antigens of the DC vaccine, so that the problem that autologous tumor antigens are difficult to obtain is solved. Furthermore, Panc-1 and AsPC-1 lysates are adopted as antigens of the DC vaccine, and the mixed lysates contain abundant and wide tumor antigens and can prevent immune escape of tumors.

The invention discloses a bipeptide modified bionic nano-vesicle as well as a preparation method and application thereof, and belongs to the field of biological medicines. The dipeptide modified bionic nano-vesicle comprises nano-particles formed by PLGA (poly (lactic-co-glycolic acid)), and the nano-particles are loaded with a medicine with a nerve protection or nerve repair effect; the surface of the nanoparticle is coated with a macrophage membrane for expressing RVG peptide and T7 peptide. The bipeptide modified bionic nano-vesicle simultaneously presents T7 peptide and RVG peptide through an engineered macrophage membrane, the T7 peptide is combined with a blood-brain barrier transferrin receptor through high affinity to realize efficient brain entry, astrocytes in the brain are specifically recognized by virtue of the RVG peptide, accurate recognition and delivery of target cells in a focus area are realized, and the bipeptide modified bionic nano-vesicle has a good application prospect. Meanwhile, the natural inflammation tropism and immune escape ability of a macrophage membrane are reserved, and the problems that a traditional drug delivery system is low in targeting precision, and cross-barrier distribution and intracerebral distribution are difficult to cooperate are solved.

The present application belongs to the technical field of medicine. Disclosed are a tumor vaccine, and a preparation method therefor and the use thereof. The raw materials of the tumor vaccine comprise a bacterial cell membrane and a liposome complex, wherein the raw materials of the liposome complex comprise a liposome and an aromatic lipid compound. The tumor vaccine provided includes the bacterial cell membrane and the liposome compound, wherein the liposome compound can fuse cells, the bacterial cell membrane can activate immunity, and the two used in combination can generate an excellent synergistic effect. Therefore, the immune escape state of the tumor cells is changed, DC cells infiltrating the tumor tissue can recognize and phagocytize tumor cells, and tumor antigens are presented, so that an in situ tumor vaccine is formed to achieve the anti-tumor effect. Moreover, the tumor vaccine provided has conventional raw materials, a simple preparation method, and good uniformity, which are beneficial to practical production and application.

The present invention provides: a novel human monoclonal antibody that binds to the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neutralizes SARS-CoV-2; an antigen-binding fragment thereof; a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof; therefore, provided are: a human monoclonal antibody against SARS-CoV-2 coronavirus that binds to the S protein of the SARS-CoV-2 coronavirus and neutralizes the viral activity thereof including an immune escape mutation; an antigen-binding fragment thereof; a nucleic acid encoding the same; and a pharmaceutical composition for the treatment or prevention of SARS-CoV-2 coronavirus infection, comprising the antibody or the antigen-binding fragment thereof.

The invention discloses a tumor vaccine as well as a preparation method and application thereof, and belongs to the technical field of medicines. The tumor vaccine is prepared from the following raw materials: a bacterial cell membrane and a lipidosome compound, the lipidosome compound is prepared from the following raw materials: lipidosome and an aromatic lipid compound. According to the tumor vaccine provided by the invention, the bacterial cell membrane and the liposome compound are included, the liposome compound can fuse cells, the bacterial cell membrane can activate immunity, and the combination of the liposome compound and the bacterial cell membrane can achieve an excellent synergistic effect, so that tumor cells are changed from an immune escape state; the DC cells infiltrated in the tumor tissue can recognize and phagocytize the tumor cells, and then the tumor antigen is presented, so that the in-situ tumor vaccine is formed, and the anti-tumor effect is achieved. The tumor vaccine provided by the invention has the advantages of conventional raw materials, simple preparation method and good uniformity, and is beneficial to actual production and application.

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen / LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

The invention discloses preparation and application of an ovarian cancer cell membrane bionic nano sound-sensitive agent, and belongs to the field of pharmacy. The technical problem to be solved by the invention is to provide the preparation method of the ovarian cancer cell membrane bionic nano sound-sensitive agent. The method is based on the homologous targeting property and immune escape property of an ovarian cancer cell membrane to ovarian tumor cells, the SKOV-3 source ovarian cancer cell membrane (CCM) is innovatively coated on the surfaces of mesoporous silica-titanium nanoparticles (MSTN) encapsulated by manganese dioxide (BSA-MnO2), and a water-soluble sound-sensitive agent azoic compound 2, 2 ', 2', 2 '-tetramethyldisiloxane is added into the mesoporous silica-titanium nanoparticles (MSTN) to prepare the SKOV-3 source ovarian cancer cell membrane. And encapsulating 2, 2 '-azobis [2-(2-imidazoline-2-yl) propane] dihydrochloride (AIPH) into mesopores of the MSTN to prepare the ovarian cancer cell membrane bionic nano sound-sensitive agent. The ovarian cancer cell membrane bionic nano sound-sensitive agent prepared by the invention is high in biocompatibility, strong in targeting specificity and good in stability, and can effectively escape from immune system recognition and elimination. On the basis, the ovarian cancer cell membrane bionic nano sound-sensitive agent can effectively realize targeted ultrasound and magnetic resonance (MRI) bimodal imaging of the sound-sensitive agent to ovarian cancer cells, effectively realize fixed-point and quantitative release of drugs, achieve adjustable diagnosis and treatment of ovarian cancer, and is expected to provide a new thought for clinical early diagnosis and precise treatment of ovarian cancer.

The invention discloses bionic nanoparticles, a composition, a preparation method and application thereof, and relates to the technical field of red blood cell-cancer cell hybrid membrane bionics. The bionic nanoparticles comprise lipidosome and a hybrid membrane coated on the surface of the lipidosome, drugs are coated in the lipidosome, and the drugs are astragaloside and curcumin; the molar ratio of the medicine to the liposome is 1: 15; the hybrid membrane is a hybrid membrane of an erythrocyte membrane and a cancer cell membrane. The erythrocyte-cancer cell hybrid membrane wraps the outer layer of the liposome phospholipid bilayer to construct the nano targeting drug delivery system, the modification of the hybrid cell membrane integrates the advantages of long circulation, immune escape, homologous targeting and the like, and a new treatment mode is developed for immunotherapy of malignant tumors with low response rate. The hybrid membrane can improve the targeting property of the drug, reduce side effects on patients and improve the tolerance of the patients. The medicine can be coated in an aqueous solution layer of the liposome, so that the water solubility of the medicine is improved, and meanwhile, the anti-tumor effect of the medicine can be enhanced.

The invention belongs to the technical field of biomedicine, and particularly relates to a zwitter-ion liposome for delivering siRNA and a preparation method and application of the zwitter-ion liposome. According to the preparation method disclosed by the invention, the liposome PMPC-Lipo modified by the zwitterionic polymer PMPC is prepared. The liposome can efficiently pass through BBB and target GBM by utilizing the structural similarity of PMPC and neurotransmitter, and is used for accurately delivering siRNA, so that safe and effective treatment on brain glioma is realized. Meanwhile, the super-hydrophilicity of the PMPC is utilized, so that the prepared PMPC-Lipo has good immune escape ability and relatively low liver accumulation amount when being intersected with the traditional PEG-Lipo, the in-vivo circulation ability is remarkably enhanced, siRNA can be effectively loaded, and the stability of a nucleic acid medicine in blood is improved, so that the brain glioma can be treated more efficiently.

The invention discloses application of a palmitoylation inhibitor in prevention and treatment of gastric cancer. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.

The invention relates to the technical field of medical chemistry and tumor treatment, in particular to application of a novel NOX4 inhibitor ZZU026 and derivatives thereof in tumor resistance and immune response change. The preparation method of the ZZU026 comprises the following steps: replacing N, N-dimethylamino on a benzene ring of GKT137831 with morpholinyl; methoxyl is introduced into the core skeleton. The ZZU026 has a remarkable inhibiting effect on NOX4, has the functions of inhibiting tumor growth, new vascularization and immune-related diseases, regulating and controlling polarization of macrophages and the like, and can inhibit phenotype transformation of macrophages from M1 to M2 and finally inhibit proliferation and immune escape of lung cancer cells; the ZZU026 and the derivatives thereof can be prepared into drugs, health care products, tablets, particles, capsules, oral liquid or injection, and can be used for treating lung cancer and other tumors.

The invention relates to the technical field of biological medicines, in particular to a preparation method of an inhibitor targeting a MAX-PD-L1 promoter specific binding motif and a double-target inhibitor, through ChIP-seq and site-directed mutagenesis experiments, a core binding motif of MAX and a PD-L1 promoter, such as 5 '-CAC [GA] TG-3', is defined, it is ensured that the inhibitor only targets a key site of MAX-PD-L1 interaction, and the activity of the MAX-PD-L1 promoter specific binding motif is improved. The off-target effect is avoided, and a high-specificity target spot is provided for subsequent inhibitor design. The cell permeability of the DNA aptamer screened based on the specific binding motif is improved after cholesterol modification, and the affinity of the DNA aptamer is obviously higher than that of a traditional antibody. A small molecule compound virtually screened through a molecular docking model is optimized through hydrogen bond and hydrophobic interaction, and then the binding affinity with MAX is improved. After treatment with the inhibitor, the combination inhibition rate of MAX and the PD-L1 promoter is high, the transcriptional activity of PD-L1 is obviously reduced, the killing rate of T cells to tumor cells is also improved, and immune escape is effectively blocked.

Therapeutic agents that can place bulky proteins, such as CD45, CD148, and CD43, at the center of the cellular interface between graft cells and CD45-positive host effector cells (e.g., T cells, NK cells, B cells, or dendritic cells) are disclosed, as are methods of their use and products made with such therapeutic agents. The therapeutic agents prevent or inhibit the formation of functional immunological synapses (including physiological SMACs). They also result in the continuous dephosphorylation of signaling pathways.

The invention discloses an application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.

The invention belongs to the technical field of medical materials, and particularly relates to magnetic control nano-enzyme hydrogel as well as a preparation method and application thereof. The FeSr MOF-coated PtNi is coated and modified by using an azide-modified macrophage membrane, the obtained PtNi / MIL-coated Mem has certain targeting property, a bacterial infection part can be recognized and enriched by using signal molecules and antibodies on the surface of the macrophage, the targeting property and the stability of nano-particle delivery are enhanced, the retention time of nano-enzyme after gel forming is longer, and the nano-enzyme is more stable and more stable. The treatment effect is better. The natural immune escape characteristic and biocompatibility of the macrophage membrane are utilized, and the application has remarkable advantages in the aspect of reducing immunological rejection and adverse reaction. In addition, the magnetic control nano-enzyme hydrogel can generate a large amount of ROS under the action of a magnetic field to destroy bacterial biofilms and kill bacteria, and controllable release of ROS is achieved. Meanwhile, Sr < 2 + > is released when the magnetic control nano-enzyme injectable hydrogel is degraded, angiogenesis is promoted, wound repair is promoted, and wound infection can be effectively treated.

The application discloses a recombinant oncolytic virus targeting CD317 gene and application thereof in anti-tumor, and belongs to the technical field of tumor treatment. The recombinant oncolytic virus comprises a CD317 inhibitor and an oncolytic virus, and is formed by integrating the CD317 inhibitor into the oncolytic virus genome. The CD317 inhibitor is a substance capable of inhibiting CD317 gene expression or targeting degradation of CD317 protein function, and is selected from shRNA or siRNA targeting CD317. The application develops the oncolytic virus targeting knockdown of CD317 expression, inhibits tumor cell proliferation by reducing CD317 expression of tumor cells, reduces PD-L1 expression so as to break the immune escape mechanism, simultaneously enhances the killing sensitivity of tumor cells to CD8+ T cells, forms a synergistic effect with the oncolysis of the oncolytic virus, and the recombinant oncolytic virus has stronger in-vivo anti-tumor activity, thereby providing a new potential scheme for CD317-driven tumor treatment.